Pharmacokinetics of Imeglimin in Hepatic Impaired Subjects

Inclusion Criteria: * Caucasian * BMI :18.0 and 40.0 kg/m2 and weight ≥50 kg. * Stable hepatic impairment or normal hepatic function for healthy volunteer * No clinically significant findings from medical history, physical examination, 12-lead ECG, vital sign measurements, and clinical laboratory evaluations (Subjects with moderate hepatic impairment may have medical findings consistent with their hepatic dysfunction) * Females will not be pregnant or lactating, and females of childbearing potential and males will agree to use contraception * Informed consent signature Exclusion Criteria: * Clinically relevant abnormal findings at the screening assessment * Severe adverse reaction to any drug or sensitivity to the trial medication or its componentsClinically significant vital signs outside the acceptable range at screening * History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs * Drug or alcohol abuse * Positive test HIV * Smoking more than 10 cig/day * Participation in other clinical trials of unlicensed or prescription medicines Exclusion criteria for healthy volunteer * Positive test for HBV, HBC * eGFR less than 90 mL/min/1.73 m2 * liver diseases Exclusion criteria for hepatic impaired * eGFR less than 80 mL/min/1.73 m2 * Hepatic impairment due to non liver disease * History of hepatocellular carcinoma or acute liver disease * CLinically significant change in liver disease status within 6 months * ascites * encephalopathy grade III or IV